Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 23;132(8):777-781.
doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma

Victor A Chow  1   2   3 , Mazyar Shadman  1   2   3 , Ajay K Gopal  1   2   3
Affiliations
Review

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma

Victor A Chow et al. Blood. .

Abstract

Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) for large B-cell lymphomas after 2 prior lines of therapy. Durable remissions are seen in 30% to 40% of study-treated patients, but toxicities of cytokine release syndrome and neurotoxicity require administration in specialized centers. This article reviews data of current diffuse large B-cell lymphoma management, focusing on axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.S. provides consultancy for Abbvie, Genentech, and Sound Biologics; is on the advisory board for Abbvie, Genentech, and Verastem; and receives research funding from Mustang Biopharma, Pharmacyclics, Gilead, Genentech, TG Therapeutics, Bigene, Acerta, Emergent, and Merck. A.K.G. reports grants and nonfinancial support from Teva, Bristol-Myers Squibb, Merck, Takeda, TG Therapeutics, and Effector; grants, personal fees, and nonfinancial support from Seattle Genetics, Pfizer, Janssen, Gilead, Spectrum, and Incyte; and personal fees from Aptevo, BRIM Bio, Seattle Genetics, and Sanofi. V.A.C. declares no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Proposed schema for use of anti-CD19 CAR T-cell therapy in clinical practice. PR, partial response; Rx, treatment. *Proceed to salvage 2 or CAR T-cell therapy. †Proceed to salvage 2, CAR T-cell therapy, or ASCT. ‡Proceed to CAR T-cell therapy ± salvage 3.
See this image and copyright information in PMC

References

    1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-459. - PubMed
    1. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011; 2011:498-505. - PubMed
    1. Van Den Neste E, Schmitz N, Mounier N, et al. . Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216-221. - PubMed
    1. Gisselbrecht C, Glass B, Mounier N, et al. . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190. - PMC - PubMed
    1. Fenske TS, Hamadani M, Cohen JB, et al. . Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients. Biol Blood Marrow Transplant. 2016;22(9):1543-1551. - PMC - PubMed

Publication types

MeSH terms